Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Guy

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
BJU International|May 9, 2013
Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomySophie Hurel, Morgan Rouprêt, Adil Ouzzane, et al.
BJU International|August 14, 2013
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumoursClémence Hollande, Pierre Colin, Thibault de La Motte Rouge, et al.
Annals of Surgical Oncology|June 22, 2011
Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative studyMehdi Mokhtar Ariane, Pierre Colin, Adil Ouzzane, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
European Urology|June 30, 2021
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Oncogene|August 16, 2023
Persistent organic pollutants promote aggressiveness in prostate cancerJulio Buñay, Myriam Kossai, Christelle Damon-Soubeyrant, et al.
European Urology Open Science|April 8, 2024
Preparing for the Worst: Management and Predictive Factors of Open Conversion During Minimally Invasive Renal Tumor Surgery (UroCCR-135 Study)Nicolas Branger, Nicolas Doumerc, Thibaut Waeckel, et al.
Annals of Surgery|April 9, 2011
Outcome and cost analysis of sacral nerve modulation for treating urinary and/or fecal incontinenceAnne-Marie Leroi, Xavier Lenne, Benoît Dervaux, et al.
European Urology Open Science|December 1, 2025
Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide CohortArthur Peyrottes, Edouard Auclin, Marc-Olivier Timsit, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
BJU International|May 9, 2013
Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomySophie Hurel, Morgan Rouprêt, Adil Ouzzane, et al.
BJU International|August 14, 2013
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumoursClémence Hollande, Pierre Colin, Thibault de La Motte Rouge, et al.
Annals of Surgical Oncology|June 22, 2011
Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative studyMehdi Mokhtar Ariane, Pierre Colin, Adil Ouzzane, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
European Urology|June 30, 2021
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
Oncogene|August 16, 2023
Persistent organic pollutants promote aggressiveness in prostate cancerJulio Buñay, Myriam Kossai, Christelle Damon-Soubeyrant, et al.
European Urology Open Science|April 8, 2024
Preparing for the Worst: Management and Predictive Factors of Open Conversion During Minimally Invasive Renal Tumor Surgery (UroCCR-135 Study)Nicolas Branger, Nicolas Doumerc, Thibaut Waeckel, et al.
Annals of Surgery|April 9, 2011
Outcome and cost analysis of sacral nerve modulation for treating urinary and/or fecal incontinenceAnne-Marie Leroi, Xavier Lenne, Benoît Dervaux, et al.
European Urology Open Science|December 1, 2025
Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide CohortArthur Peyrottes, Edouard Auclin, Marc-Olivier Timsit, et al.
Pageof 9